Yahoo
NYSE - Nasdaq Real Time Price USD

Johnson & Johnson (JNJ)

275.08 +4.04 (+1.49%)
As of 10:52:57 AM EDT. Market Open.
Trade JNJ on Coinbase
Dividend
JNJ announced a cash dividend of $1.34 with an ex-date of Nov. 24, 2026

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Joaquin Duato
CEO & Chairman 6.5M 16.44M 1963
Mr. Joseph James Wolk CPA
Executive VP & CFO 3.22M 1.96M 1967
Dr. John C. Reed M.D., Ph.D.
Executive Vice President of Innovative Medicine and R&D 3.17M 755.62k 1958
Mr. Timothy Schmid
Executive VP & Worldwide Chairman of MedTech 2.54M -- 1970
Mr. Robert J. Decker Jr.
Controller & Chief Accounting Officer -- -- 1973
Mr. James Swanson
Executive VP & Chief Information Officer -- -- 1966
Mr. Ryan Koors
Vice President of Investor Relations -- -- --
Mr. Dirk Brinckman
Chief Compliance Officer -- -- --
Ms. Elizabeth Forminard J.D.
Executive VP & Chief Legal Officer -- -- 1971
Ms. Kristen Blair Mulholland
Executive VP & Chief Human Resources Officer -- -- 1967

Johnson & Johnson

One Johnson & Johnson Plaza
New Brunswick, NJ 08933
United States
732 524 0400 https://www.jnj.com
Sector: 
Healthcare
Full Time Employees: 
138,200

Description

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Corporate Governance

Johnson & Johnson’s ISS Governance QualityScore as of October 1, 2026 is 4. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 3; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 13, 2026 at 12:30 PM UTC

Johnson & Johnson Earnings Date

November 24, 2026 at 12:00 AM UTC

Ex-Dividend Date

December 8, 2026 at 12:00 AM UTC

Dividend Date

Recent Events

October 21, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 13, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 11, 2026 at 12:00 AM UTC

N-PX: Annual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX

August 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 29, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 28, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 23, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 15, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 25, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

May 27, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: